Pipeline › exenatide

exenatide

FDA-approved since 2005 and marketed in the US as Bydureon, Byetta, Exenatide, authorised in the EU as Bydureon, Byetta, with no open FDA shortage or discontinuation records. 5 active trials.

GLP-1 agonist, SC, from AstraZeneca. Every figure below is taken directly from ClinicalTrials.gov, Drugs@FDA, the FDA Drug Shortage Database, the EMA register or Europe PMC, and re-checked every four hours.

Status: marketed
Target: GLP-1
Route: SC
Sponsor: AstraZeneca
Brand names: Bydureon, Byetta, Exenatide
First FDA approval: 2005-04-28
EU authorisation: Bydureon (2017), Byetta (2018)
Active trials: 5 (3 in phase 3)
Participants enrolled: 487
Trials with a reporting date: 0
Approved FDA submissions: 90

Approved indications

Quoted from the current FDA label for each application. This is what the drug is approved to treat in the US — separate from the conditions it is being studied in.

Exenatide ANDA206697

label effective 2026-05-27 · full label

Exenatide injection is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Exenatide injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 , 14 ) Limitations of Use Co-administration with other exenatide-containing products is not recommended. ( 1 ) Limitations of Use Exenatide injection contains exenatide. Co-administration with other exenatide-containing products is not recommended.

type 2 diabetes

Byetta NDA021773

label effective 2025-09-02 · full label

BYETTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use • BYETTA contains exenatide. Coadministration with other exenatide-containing products is not recommended. BYETTA (exenatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 , 14 ) Limitations of Use • Coadministration with other exenatide-containing products is not recommended ( 1 ).

type 2 diabetes

Recent changes

Detected	Change	Trial
2026-10-09	New trial registered	· AMNEAL
2026-10-09	New trial registered	· AMNEAL
2026-10-09	New trial registered	· AMNEAL

Regulatory history

Date	Action	Brands	Application
2026-10-02	Labeling	EXENATIDE SYNTHETIC	ANDA206697
2026-10-02	Labeling	EXENATIDE SYNTHETIC	ANDA206697
2026-10-02	Labeling	EXENATIDE SYNTHETIC	ANDA206697
2025-09-02	Labeling	BYETTA	NDA021773 · label
2025-05-28	Labeling	BYETTA	NDA021773 · label
2025-05-28	Labeling	BYDUREON, BYDUREON PEN	NDA022200 · label
2025-05-28	Labeling	BYDUREON BCISE	NDA209210 · label
2024-11-19	Generic approval (ANDA) original	EXENATIDE SYNTHETIC	ANDA206697
2024-11-01	Labeling	BYETTA	NDA021773 · label
2024-11-01	Labeling	BYDUREON, BYDUREON PEN	NDA022200 · label
2024-11-01	Labeling	BYDUREON BCISE	NDA209210 · label
2024-03-06	Labeling	BYDUREON BCISE	NDA209210 · label
2022-12-21	Labeling	BYETTA	NDA021773 · label
2022-12-21	Labeling	BYDUREON, BYDUREON PEN	NDA022200 · label
2022-12-21	Labeling	BYDUREON BCISE	NDA209210 · label
2022-07-26	Labeling	BYDUREON, BYDUREON PEN	NDA022200 · label
2022-07-26	Labeling	BYDUREON BCISE	NDA209210 · label
2022-06-10	Labeling	BYETTA	NDA021773 · label
2022-06-10	Labeling	BYETTA	NDA021773 · label
2022-06-10	Labeling	BYDUREON, BYDUREON PEN	NDA022200 · label
2022-06-10	Labeling	BYDUREON BCISE	NDA209210 · label
2021-11-04	Efficacy	BYETTA	NDA021773 · label
2021-07-22	Efficacy	BYDUREON, BYDUREON PEN	NDA022200 · label
2021-07-22	Efficacy	BYDUREON BCISE	NDA209210 · label
2021-06-17	Labeling	BYETTA	NDA021773 · label

Indications under study

Childhood Obesity; Gestational Diabetes; Multiple Sclerosis; Type 1 Diabetes Mellitus; Type 2 Diabetes Mellitus.

Recent papers

Published	Title	Journal
2026-10-01	Genetically proxied GLP1R expression does not predict exenatide response in the Exenatide-PD3 trial Gurney R, Girges C, Vijiaratnam N, Athauda D, Gandhi S, Morris H, Foltynie T.	Brain
2026-10-01	Reply: Genetically proxied GLP1R expression does not predict exenatide response in the Exenatide-PD3 trial Woo KA, Jang Y, Kim HJ, Park PJ.	Brain
2026-09-24	Mechanistic insights into the inhibition of insulin amyloidogenesis and associated toxicity by the p.M14L variant of exenatide Bahrami Z, Shalgahi MR, Shahsavani MB, Mirzaei Z, Zarei I, Amanlou M, Farjadian F, Moosavi-Movahedi AA, Yousefi R.	FEBS J
2026-09-18	Development of chondroitin sulfate‑stabilized PLGA microspheres of exenatide via polarity gradient extraction Khopade AJ, Halder A, Patel V, Joshi M, Burade V.	Pharm Dev Technol
2026-07-15	Exenatide Attenuates Doxorubicin-Induced Acute Hepatic Injury Through Modulation of SIRT1-HMGB1 Signaling and Oxidative Stress Karakullukcu HK, Gül SS, Aygun H, Kalın M, Karakullukcu M, Arslan A, Özkan ÖF, Ercan G.	Pharmaceuticals (Basel)
2026-06-22	Expression of Concern: Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial The Editors Of The Lancet.	Lancet
2026-06-15	Effects of insulin and exenatide therapy on glycemic control and β-cell function in patients newly diagnosed with type 2 diabetes and severe hyperglycemia Wu TH, Kuo CS, Chen HS.	J Chin Med Assoc
2026-06-11	Change in circulating irisin level and its association with lipid metabolism after exenatide treatment in patients with type 2 diabetes mellitus Gao Y, Hong X, Yang K, Le Y, Wei R, Yang J, Hong T, Tian Q.	J Clin Transl Endocrinol
2026-06-02	The GLP-1 Agonist Exenatide Is Associated with Improved Adherence to Health Behavior and Lifestyle Treatment in Adolescents with Obesity: A Randomized Controlled Trial Stenlid R, Cerenius SY, Torbahn G, Aydin BK, Ciba I, Vilén H, Mörwald K, Geiersberger S, Roomp K, Cadamuro J, Gomahr J, Lischka J, Weghuber D, Bergsten P, Forslund A, Manell H.	Obes Facts
2026-06-01	Exenatide induces an enhanced endogenous glucagon-like peptide-1 secretory response in patients receiving basal insulin Parikh M, Pu J, Shen J, Kramer CK, Zinman B, Beaudry JL, Retnakaran R.	J Clin Endocrinol Metab
2026-05-22	Hemodynamic and metabolomic responses to infusion of GLP-1 agonist exenatide in pulmonary arterial hypertension Samaranayake CB, Niglas M, Baxan N, Kempny A, Ashek A, Gatzoulis M, Price LC, Dimopoulos K, Wilkins MR, Wort S, Rhodes CJ, Zhao L, McCabe C.	JCI Insight
2026-03-20	Study on chitosan/carrageenan core-shell nanoparticles for oral co-administration of insulin/exenatide enhance insulin secretion in type 2 diabetes Nguyen TV, Cao-Luu NH, Nguyen TB, Dang HG, Luong HV.	Int J Biol Macromol
2026-03-03	Circulating GDF15 and HbA1c Response to Add-On Exenatide Therapy in Type 2 Diabetes: A Post Hoc Analysis from a Multicenter Trial Wu Q, Yang K, Liao X, Zheng S, Zheng X, Wang H, Yang J, Hong T.	Biomedicines
2026-02-24	Exenatide attenuates neuroinflammation and rescues sepsis-induced depressive behavior and cognitive dysfunction in a mouse model Liu S, Chen Q, Liu H, Chen Z, Ding N, Sun T, Wang L.	Neuroscience
2026-02-21	Exenatide through PPARδ improved hepatic insulin resistance in patients of type 2 diabetes mellitus via suppressing pyroptosis Li X, Zhou T, Wu Y, Sun J, Wang Z, Huang Y, Xu K, Ling H, Li N, Yang T, Wang T.	Int Immunopharmacol

Every exenatide trial on file

All 211 registered trials of exenatide, largest first. Each links to its own page and to the registry record.

Trial	Status	Phase	Participants
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus NCT01144338 · AstraZeneca	Completed	P3	14,752
A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650 NCT01455896 · Intarcia Therapeutics	Completed	P3	4,156
A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both. NCT00717457 · Hoffmann-La Roche	Completed	P3	1,189
A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes NCT00960661 · AstraZeneca	Completed	P3	1,036
Exenatide Versus Glimepiride in Patients With Type 2 Diabetes NCT00359762 · AstraZeneca	Completed	P3	1,029
Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) NCT00676338 · AstraZeneca	Completed	P3	820
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus NCT00035984 · AstraZeneca	Completed	P3	734
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo NCT02229396 · AstraZeneca	Completed	P3	695
A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects NCT00917267 · AstraZeneca	Completed	P3	691
GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin NCT00707031 · Sanofi	Completed	P3	639
Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy NCT04504396 · PegBio Co., Ltd.	Completed	P3	620
Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin NCT00082381 · AstraZeneca	Completed	P3	551
A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes NCT01455870 · Intarcia Therapeutics	Completed	P3	535
A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2) NCT00637273 · AstraZeneca	Completed	P3	514
Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin NCT00082407 · AstraZeneca	Completed	P3	505
Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes NCT00434954 · AstraZeneca	Completed	P3	494
Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3) NCT00641056 · AstraZeneca	Completed	P3	467
Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin NCT00324363 · AstraZeneca	Completed	P3	466
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus NCT02229383 · AstraZeneca	Completed	P3	464
A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes NCT01455857 · Intarcia Therapeutics	Completed	P3	460
Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes NCT00111540 · AstraZeneca	Completed	P3	456
The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus NCT03239119 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Unknown	P3	456
Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus NCT00935532 · AstraZeneca	Completed	P3	427
A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes NCT02119819 · OPKO Health, Inc.	Completed	P2	420
COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial NCT02404376 · Hospital Universitari Vall d'Hebron Research Institute	Completed	P3	378
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea NCT00039026 · AstraZeneca	Completed	P3	377
Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes NCT01652716 · AstraZeneca	Completed	P3	377
Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes NCT00359879 · AstraZeneca	Completed	P3	377
Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea. NCT00313001 · Novo Nordisk A/S	Completed	P3	373
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus NCT01652729 · AstraZeneca	Completed	P3	365
Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only NCT00518115 · GlaxoSmithKline	Completed	P2	361
Trial of EXenatide in Acute Ischaemic Stroke NCT03287076 · Neuroscience Trials Australia	Unknown	P2	350
Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM NCT02467920 · Huazhong University of Science and Technology	Completed	P4	349
Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide NCT00560417 · Eli Lilly and Company	Completed	P3	339
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin NCT00039013 · AstraZeneca	Completed	P3	336
Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM NCT01107717 · The University of Texas Health Science Center at San Antonio	Completed	P4	318
Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1) NCT00308139 · AstraZeneca	Completed	P3	303
An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus NCT01876849 · AstraZeneca	Completed	P3	275
Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects NCT04504370 · PegBio Co., Ltd.	Completed	P3	273
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients NCT06254014 · Beijing Dongfang Biotech Co., Ltd.	Active, not recruiting	P3	270
Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus NCT00765817 · AstraZeneca	Completed	P3	261
A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease NCT04154072 · Neuraly, Inc.	Completed	P2	255
A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin NCT00870194 · AstraZeneca	Completed	P4	255
A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5) NCT00877890 · AstraZeneca	Completed	P3	254
Weight Loss With Exenatide Treatment NCT01590433 · Jody Dushay	Completed	P4	249
Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin NCT03060980 · Intarcia Therapeutics	Terminated	P3	245
Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes. NCT02288273 · AstraZeneca	Completed	P4	239
A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients NCT00360334 · AstraZeneca	Completed	P3	235
Safety and Efficacy of Exenatide as Monotherapy NCT00381342 · AstraZeneca	Completed	P3	233
Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients With Newly Diagnosed Type 2 Diabetes NCT03297879 · Beijing Chao Yang Hospital	Completed	P4	230
Extension Study for 2993-112 NCT01789957 · AstraZeneca	Completed	P3	225
Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes NCT01003184 · AstraZeneca	Completed	P3	222
Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes NCT02081118 · Hanmi Pharmaceutical Company Limited	Completed	P2	209
A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese NCT03018665 · The First Hospital of Jilin University	Unknown	P4	200
Exenatide for Myocardial Protection During Reperfusion Study NCT01938235 · University Health Network, Toronto	Unknown	P2	198
Effect on Weight Loss of Exenatide Versus Placebo NCT00375492 · AstraZeneca	Completed	P3	196
Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease NCT04232969 · University College, London	Completed	P3	194
Research of Exenatide for Overweight/Obese PCOS Patients With IGR NCT03352869 · RenJi Hospital	Completed	P4	183
Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin NCT00099320 · AstraZeneca	Completed	P3	182
Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) NCT00577824 · AstraZeneca	Completed	P3	181
Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin NCT00603239 · AstraZeneca	Completed	P3	165
A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients NCT00500370 · AstraZeneca	Completed	P2	163
Research of Intensive Metabolic Intervention Before Pregnancy in PCOS NCT03383068 · RenJi Hospital	Unknown	P4	160
The Effects of Short-Term Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients NCT01270191 · Taipei Veterans General Hospital, Taiwan	Unknown	P4	160
Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus NCT00044694 · AstraZeneca	Completed	P2	156
Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients NCT01776788 · The First Affiliated Hospital of Xiamen University	Completed	P4	156
Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination NCT00044668 · AstraZeneca	Completed	P3	155
Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus NCT00943917 · Intarcia Therapeutics	Completed	P2	155
A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes NCT00382239 · AstraZeneca	Completed	P2	153
Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence? NCT03232112 · Anders Fink-Jensen, MD, DMSci	Completed	P2	152
Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes NCT02449603 · Xijing Hospital	Completed	P4	150
Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes NCT02455076 · Emory University	Completed	P4	150
The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects NCT00856609 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	P3	150
Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus NCT02162550 · Phoenix VA Health Care System	Unknown	P4	148
Exenatide for Smoking Cessation and Prevention of Weight Gain NCT05610800 · The University of Texas Health Science Center, Houston	Completed	P2	140
Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy NCT00099619 · AstraZeneca	Completed	P3	138
An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus NCT00135330 · AstraZeneca	Completed	P3	137
Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin NCT00753896 · AstraZeneca	Completed	P3	134
Myocardial Protection of Exenatide in AMI NCT01580514 · Kyunghee University Medical Center	Completed	P4	127
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes NCT00658021 · AstraZeneca	Completed	P3	122
A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension NCT01104701 · AstraZeneca	Completed	P2	121
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis NCT07497399 · Johns Hopkins University	Recruiting	P2	120
EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) NCT02635386 · Woman's	Completed	P3	119
Exenatide for Stress Hyperglycemia NCT01969149 · Centre Hospitalier Universitaire de Besancon	Completed	P2/P3	110
A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients. NCT02533453 · AstraZeneca	Completed	P4	110
Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes NCT01140893 · University Hospital, Caen	Unknown	P2/P3	110
Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetic Cases NCT03017352 · Filip Krag Knop	Completed	P2	108
Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria NCT03331289 · The University of Texas Health Science Center at San Antonio	Completed	P4	107
Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL) NCT02194595 · Mount Sinai Hospital, Canada	Completed	P3	105
A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus NCT00477581 · AstraZeneca	Completed	P4	102
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) NCT01524705 · University of Washington	Completed	P4	102
Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function NCT02584075 · Beijing Chao Yang Hospital	Unknown	P4	100
Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI NCT00835848 · Copenhagen University Hospital, Rigshospitalet	Completed	P4	100
Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity NCT02496611 · University of Minnesota	Completed	P2	100
Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy NCT02129985 · xiaolong zhao	Unknown	P4	100
A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c NCT01785771 · Intarcia Therapeutics	Terminated	P3	100
Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus NCT00085969 · AstraZeneca	Completed	P2	99
SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease NCT04269642 · Peptron, Inc.	Unknown	P2	99
Physical and Chemical Study of Atherosclerosis Mechanisms NCT01700075 · Nazarbayev University	Completed	P4	97
Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy NCT02690883 · Nanfang Hospital, Southern Medical University	Completed	P4	92
Liver and Fat Regulation in Overweight Adolescent Girls NCT02157974 · University of Colorado, Denver	Completed	P2/P3	92
Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM NCT02981069 · The University of Texas Health Science Center at San Antonio	Completed	P4	90
Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes NCT01554618 · AstraZeneca	Completed	P3	84
Safety and Efficacy of YH14617 in Diabetes Mellitus NCT01507038 · Yuhan Corporation	Completed	P2	84
Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione NCT00729326 · AstraZeneca	Completed	P4	83
Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin NCT00701935 · AstraZeneca	Terminated	P2	80
Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients NCT04029272 · Peking Union Medical College Hospital	Unknown	P4	80
A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes NCT01928329 · Yale University	Completed	P2	79
Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes NCT02303730 · Fudan University	Completed	P4	76
The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes NCT01181986 · Carl T. Hayden VA Medical Center	Completed	P4	76
Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment NCT01076842 · Novo Nordisk A/S	Completed	P4	75
Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy NCT01514149 · ConjuChem	Terminated	P2	73
Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus NCT01452451 · Hanmi Pharmaceutical Company Limited	Completed	P2	72
The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes NCT00353834 · Joslin Diabetes Center	Completed	P4	72
Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia NCT02417142 · University of Massachusetts, Worcester	Completed	P4	70
Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes NCT00097500 · AstraZeneca	Completed	P3	69
Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept. NCT03970044 · Consano Clinical Research, LLC	Completed	P4	67
DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2 NCT03361098 · Amsterdam UMC, location VUmc	Completed	P4	65
Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients NCT02432976 · Centre Hospitalier Universitaire de Besancon	Completed	P2/P3	64
Brain Activation and Satiety in Children 2 NCT04520490 · Seattle Children's Hospital	Active, not recruiting	P3	63
Exenatide Treatment in Parkinson's Disease NCT04305002 · Center for Neurology, Stockholm	Unknown	P2	60
Trial of Exenatide for Parkinson's Disease NCT01971242 · University College, London	Completed	P2	60
Exenatide and Metformin Therapy in Overweight Women With PCOS NCT00344851 · Metabolic Center of Louisiana Research Foundation	Completed	P2	60
Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia. NCT04969627 · Bing He	Completed	P4	60
Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes NCT02380521 · University of Palermo	Completed	P4	60
Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes NCT01435980 · Wu Qinan	Unknown	P4	60
An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes NCT00516048 · AstraZeneca	Completed	P3	58
A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease NCT01255163 · National Institute on Aging (NIA)	Terminated	P2	57
Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome NCT02251431 · Baylor Research Institute	Completed	P3	57
A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes NCT00516074 · AstraZeneca	Completed	P3	54
Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults NCT00845507 · University of Cincinnati	Completed	P4	54
The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes NCT00546728 · St. Paul Heart Clinic	Completed	P4	50
Exenatide Once-weekly as a Treatment for Multiple System Atrophy NCT04431713 · University College, London	Completed	P2	50
Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight NCT02313220 · Uppsala University	Completed	P2	50
Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents NCT00099333 · AstraZeneca	Completed	P2	49
Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes NCT00064714 · AstraZeneca	Completed	P2	47
Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue NCT01794429 · Bjorn H. Ebdrup	Completed	P3	45
Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes NCT00103935 · AstraZeneca	Completed	P2	45
Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics NCT02042664 · Assistance Publique Hopitaux De Marseille	Completed	P3	44
Double-blinded, 6 Months Study With Bydureon® or Placebo in Adolescents With Obesity to Explore Changes in BMI NCT02794402 · Uppsala University	Completed	P2	44
A Comparison of Exenatide and Insulin Glargine NCT02325960 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Completed	P4	44
Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function NCT00845182 · The University of Texas Health Science Center at San Antonio	Completed	P4	43
Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy NCT02860923 · University Hospital, Bordeaux	Completed	P3	42
Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study) NCT04897802 · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	Completed	P4	42
Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity NCT02664441 · Seattle Children's Hospital	Completed	P3	42
Safety Evaluation of Adverse Reactions in Diabetes NCT02092597 · Charles University, Czech Republic	Completed	P4	42
The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women NCT00456885 · Beth Israel Deaconess Medical Center	Completed	P4	41
How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics NCT00667732 · Oregon Health and Science University	Completed	P4	41
Long-acting Exenatide and Cognitive Decline in Dysglycemic Patients NCT02847403 · Azienda Ospedaliero-Universitaria di Parma	Unknown	P3	40
Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients NCT00736229 · Saint Luke's Health System	Completed	P4	40
Exendin-4 as a Treatment for Parkinson's Disease - Pilot Study NCT01174810 · University College, London	Unknown	P2	40
Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial) NCT01254123 · Amsterdam UMC, location VUmc	Unknown	P3	40
Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation NCT00974272 · Carl T. Hayden VA Medical Center	Completed	P4	39
Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects NCT02621489 · Karolinska Institutet	Completed	P4	38
Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass NCT01373216 · Charles University, Czech Republic	Completed	P3	38
Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia NCT01269047 · Albert Einstein College of Medicine	Completed	P4	37
The Safety,Preliminary Pharmacodynamics and Pharmacokinetics Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus NCT01342042 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Unknown	P2	36
Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus. NCT03007329 · Medical University of Vienna	Completed	P4	34
Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes NCT00948168 · Cliniques universitaires Saint-Luc- Université Catholique de Louvain	Completed	P4	34
A GLP-1 Receptor PET Imaging Substudy Within the VER-A-T1D Trial Investigating the Effects on Beta Cell Mass NCT04615910 · Radboud University Medical Center	Unknown	P2	30
The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke NCT02829502 · Christina Kruuse	Unknown	P2	30
The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers NCT02838589 · Christina Kruuse	Completed	P2	30
Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes NCT00241423 · AstraZeneca	Completed	P2	30
Bioenergetic Alterations After Exenatide Administration NCT00623545 · University of Wisconsin, Madison	Completed	P4	28
The Effects of Exenatide After Gastric Restriction NCT00872378 · Advanced Specialty Care	Unknown	P2/P3	28
Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart Failure NCT00766857 · Amsterdam UMC, location VUmc	Completed	P4	27
Exenatide in Extreme Pediatric Obesity NCT01237197 · University of Minnesota	Completed	P2	26
Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease NCT01006889 · University of Florida	Completed	P4	24
Exenatide and Brown Adipose Tissue NCT03002675 · Ingrid Jazet	Unknown	P4	24
Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes NCT01432405 · Baylor College of Medicine	Completed	P4	24
Effect of Exenatide on Liver and Heart Fat and Inflammation NCT01951651 · Baylor College of Medicine	Completed	P4	24
Exeantide in Type 2 Diabetes on Insulin NCT01154933 · University at Buffalo	Completed	P2	24
Effects of Antidiabetic Medications on the Postprandial State in Prediabetes NCT02104739 · The University of Texas Health Science Center, Houston	Completed	P4	21
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol NCT00679042 · CellTrans Inc.	Active, not recruiting	P3	21
Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying NCT02160990 · Mayo Clinic	Completed	P4	20
GLP-1 Agonism Stimulates Browning of Subcutaneous White Adipose Tissue in Obesity Men NCT02170324 · Xiang Guang-da	Completed	P4	20
Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus NCT01235819 · Command Hospital, India	Completed	P4	20
BetaFIT Study: Beta Cell Imaging After Faecal mIcrobiota Transplantation NCT05622123 · Radboud University Medical Center	Unknown	P2	20
A Study With NLY01 in Subjects With Type 2 Diabetes NCT04159766 · Neuraly, Inc.	Completed	P2	20
The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes NCT00950677 · Baylor College of Medicine	Completed	P4	16
Acute Effect of Exenatide on Brain Glucose Metabolism NCT01588418 · The University of Texas Health Science Center at San Antonio	Completed	P4	15
GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes NCT03029351 · University at Buffalo	Terminated	P4	15
A Trial to Determine the Efficacy and Safety of Presendin in IIH NCT05347147 · Invex Therapeutics Ltd.	Terminated	P3	14
Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist NCT01381926 · University of Alabama at Birmingham	Terminated	P4	14
Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes NCT05482789 · Maisa N. Feghali, MD	Recruiting	P4	13
Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) NCT01208649 · Ruhr University of Bochum	Completed	P4	13
The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients NCT03419624 · Universitätsklinikum Hamburg-Eppendorf	Terminated	P3	13
New Onset Type 1 Diabetes: Role of Exenatide NCT01269034 · Albert Einstein College of Medicine	Completed	P4	13
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus NCT00254254 · AstraZeneca	Completed	P2	13
GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children NCT00886626 · University of Minnesota	Completed	P2	12
Role of Exenatide in Type 1 Diabetes NCT00456300 · Montefiore Medical Center	Completed	P2	11
Exenatide and Impaired Hypoglycaemic Awareness in Type 1 Diabetes NCT02735031 · Radboud University Medical Center	Completed	P2/P3	10
Effect of Exenatide on Cortisol Secretion NCT03160261 · University of Tartu	Completed	P4	10
Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor NCT01484873 · Vanderbilt University Medical Center	Completed	P2	10
Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes NCT04307797 · Cambridge University Hospitals NHS Foundation Trust	Completed	P4	10
Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation NCT03961256 · Mayo Clinic	Completed	P2	9
Intravenous Exenatide in Patients With Acute Brain Injury NCT02058940 · University of North Carolina, Chapel Hill	Completed	P4	8
Role of Exenatide in NASH-a Pilot Study NCT00650546 · Indiana University	Completed	P2/P3	8
The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET NCT00747968 · University of Aarhus	Completed	P2/P3	8
Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults NCT01791465 · Vanderbilt University	Terminated	P4	6
A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects NCT02802514 · GlaxoSmithKline	Terminated	P4	5
An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects NCT02793154 · GlaxoSmithKline	Terminated	P4	4
Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure NCT00799435 · Baylor College of Medicine	Terminated	P4	2
Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease NCT00529204 · University of California, Davis	Terminated	P2	1
Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes NCT02811484 · Weill Medical College of Cornell University	Withdrawn	P4	—
Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes NCT00572689 · Georgetown University	Withdrawn	P4	—
The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young Adults NCT00845559 · Yale University	Withdrawn	P4	—
Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome NCT01818648 · Mayo Clinic	Withdrawn	P4	—
A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes NCT01455883 · Intarcia Therapeutics	Withdrawn	P3	—
A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes NCT01455909 · Intarcia Therapeutics	Withdrawn	P3	—
A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes NCT01455922 · Intarcia Therapeutics	Withdrawn	P3	—